LUX INDUSTRIES: CO HAS RECOMMENDED DIVIDEND OF 2 RUPEES PER EQUITY SHARE

LUX INDUSTRIES: Q4 EBITDA 770M RUPEES VS 755.5M (YOY) || Q4 EBITDA MARGIN 9.42% VS 10.55% (YOY)

LUX INDUSTRIES: Q4 CONS NET PROFIT 481M RUPEES VS 555.4M (YOY); 321M (QOQ) || Q4 REVENUE 8.2B RUPEES VS 7.16B (YOY)

HIKAL: CO SAYS JIGANI FACILITY FDA INSPECTION CLASSIFIED AS 'OFFICIAL ACTION INDICATED' || CO REMAINS COMMITTED TO WORK CLOSELY WITH THE US FDA AND MAINTAINING THE HIGHEST QUALITY AND COMPLIANT MANUFACTURING STANDARDS AT ALL OF ITS FACILITIES AND ENHANCE ITS COMPLIANCE ON AN ONGOING BASIS

LINDE INDIA: CO HAS RECOMMENDED DIVIDEND OF 12 RUPEES PER EQUITY SHARE

LINDE INDIA: Q4 EBITDA 2.1B RUPEES VS 1.8B (YOY) || Q4 EBITDA MARGIN 35.46% VS 28.5% (YOY)

LINDE INDIA: Q4 CONS NET PROFIT 1.2B RUPEES VS 1.05B (YOY); 1.16B (QOQ) || Q4 REVENUE 5.9B RUPEES VS 6.3B (YOY)

20 MICRONS: CO HAS RECOMMENDED A FINAL DIVIDEND OF 1.25 RUPEES PER EQUITY SHARE

20 MICRONS: Q4 EBITDA 290M RUPEES VS 265.4M (YOY) || Q4 EBITDA MARGIN 12.75% VS 12.5% (YOY)

20 MICRONS: Q4 CONS NET PROFIT 152M RUPEES VS 136.4M (YOY); 129M (QOQ) || Q4 REVENUE 2.3B RUPEES VS 2.12B (YOY)

SUN PHARMA: CO ENTERS AGREEMENT WITH PHARMAZZ INC || CO TO INVEST UP TO $25M IN PHARMAZZ INC

UNITED SPIRITS: CO EXEC SAYS DUTY REDUCTION TO SPUR HIGH SINGLE DIGIT ADDITIONAL VOLUME GROWTH || CO EXEC SAYS MARGINS LIKELY TO BE RANGE BOUND IN THE NEXT COUPLE OF YEARS

UNITED SPIRITS: CO EXEC SAYS DUTY REDUCTION FROM 150% TO 75% COULD LEAD TO HIGH SINGLE DIGIT PRICE REDUCTION || CO SAYS DUTY REDUCTION BENEFITS WILL START COMING AROUND FY27

CAMLIN FINE SCIENCES: Q4 EBITDA 594M RUPEES VS 315M (YOY) || Q4 EBITDA MARGIN 13.58% VS 8.35% (YOY)

CAMLIN FINE SCIENCES: Q4 CONS NET LOSS 7M RUPEES VS LOSS 771M (YOY); LOSS 41M (QOQ) || Q4 REVENUE 4.4B RUPEES VS 3.8B (YOY)

HERANBA INDUSTRIES: CO HAS RECOMMENDED A FINAL DIVIDEND OF 1 RUPEE PER EQUITY SHARE

HERANBA INDUSTRIES: Q4 EBITDA LOSS 10M RUPEES VS GAIN 196M (YOY)